

Ironwood Pharma announces Linzess approval in China

16 January 2019 | News

Ironwood anticipates that it will launch the drug with its partner in China, AstraZeneca, in the second half of 2019.



Ironwood Pharmaceuticals, Inc., a US based commercial biotechnology company, has announced that the National Medical Products Administration (NMPA) approved the marketing application for LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) in China. Ironwood anticipates that it will launch the drug with its partner in China, AstraZeneca, in the second half of 2019.

Linaclotide is a guanylate cyclase-C (GC-C) receptor agonist currently approved and available for the treatment of adults with IBS-C or chronic idiopathic constipation (CIC) in the United States and more than 30 other countries.

Ironwood is partnered with AstraZeneca for development and commercialization of linaclotide in China, Hong Kong and Macau. Astellas also has the exclusive rights to develop and commercialize linaclotide in Japan.